FY2018 EPS Estimates for Seres Therapeutics Inc (MCRB) Lifted by Cantor Fitzgerald
Seres Therapeutics Inc (NASDAQ:MCRB) – Research analysts at Cantor Fitzgerald increased their FY2018 earnings per share (EPS) estimates for Seres Therapeutics in a research report issued on Sunday. Cantor Fitzgerald analyst W. Tanner now expects that the biotechnology company will post earnings per share of ($2.37) for the year, up from their prior forecast of ($2.72).
A number of other equities research analysts have also commented on the stock. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, December 5th. BidaskClub lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $18.00.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.71) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.02. Seres Therapeutics had a negative net margin of 278.44% and a negative return on equity of 103.46%. The company had revenue of $3.06 million for the quarter, compared to analyst estimates of $3.00 million.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in Seres Therapeutics during the third quarter worth $2,165,000. Northern Trust Corp raised its holdings in Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock worth $2,664,000 after buying an additional 32,875 shares during the last quarter. Lakeview Capital Partners LLC acquired a new position in Seres Therapeutics during the fourth quarter worth $346,000. JPMorgan Chase & Co. raised its holdings in Seres Therapeutics by 39.9% during the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after buying an additional 106,479 shares during the last quarter. Finally, State Street Corp raised its holdings in Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after buying an additional 34,393 shares during the last quarter. 81.43% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “FY2018 EPS Estimates for Seres Therapeutics Inc (MCRB) Lifted by Cantor Fitzgerald” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/03/14/fy2018-eps-estimates-for-seres-therapeutics-inc-mcrb-lifted-by-cantor-fitzgerald.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.